Iter-4360dd15-0123-transcript
第 123 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 erratum abstract corrected sentence PMC4713958 investigator assessed PFS"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0120-transcript", "tags": "iteration transcript", "modified": "20260424220420000", "preview": "!! 第 120 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 erratum investigator assessed PFS abstract metadata\"}) → call list_recent({\"n\":6}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0120-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424220420000\", \"preview\": \"!! 第 120 轮执行轨"}, {"title": "Iter-4360dd15-0114-transcript", "tags": "iteration transcript", "modified": "20260424215258000", "preview": "!! 第 114 轮执行轨迹 → call read_note({"title":"NEXT_FOCUS"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0122）\n\n逐字比对原摘要与 erratum 修订句，确认最终应引用的精确表述。"}
→ call list_recent({"n":6})
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 PMC4713958 abstract corrected sentence original sentence"})
【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0122-reflection", "modified": "20260424220712000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424220712000", "tags": "pinned focus"}, {"title": "先判更正范围再定引用文本", "modified": "20260424220712000", "tags": "lesson erratum verification evidence-chain"}, {"title": "Iter-4360dd15-0122-transcript", "modified": "20260424220700000", "tags": "iteration transcript"}, {"title": "BOLERO-2 abstract should cite erratum-corrected subgroup wording", "modified": "20260424220656000", "tags": "fact knowledge 4360dd15 clinical-trials erratum evidence-chain"}, {"title": "Iter-4360dd15-0121-reflection", "modified": "20260424220536000", "tags": "iteration reflection"}]}
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 38310895 NEXT_FOCUS 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":10}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 38310895 原始人类试验 PMID 主要终点\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":8,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": → call web_search({"limit":5,"query":"PMC4713958 BOLERO-2 erratum abstract corrected sentence"})
→ call pubmed_search({"limit":5,"query":"BOLERO-2 everolimus exemestane erratum abstract"})
→ call web_search({"limit":5,"query":"BOLERO-2 abstract erratum investigator-assessed progression-free survival PMC"})
【tool:web_search】
{"ok": true, "query": "PMC4713958 BOLERO-2 erratum abstract corrected sentence", "results": [{"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "snippet": "In the Abstract , patients with disease recurrence during or within 12 months of completion of adjuvant therapy are grouped with other patient subgroups as being \"prospectively defined\". This subgroup was not included within the prospectively defined patient subgroups for the BOLERO-2 trial."}, {"title": "Sentence Checker", "url": "https://sentencechecker.com/", "snippet": "Free online spell and grammar checker based on LanguageTool - an open source proofreading software."}, {"title": "Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Europe PMC", "url": "https://europepmc.org/article/PMC/PMC4713958", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis"}, {"title": "Free Grammar Checker (Online Editor)", "url": "https://www.grammarcheck.net/editor/", "snippet": "To check your text, copy and paste or write directly into the online editor above. Click the Free Check button to check grammar, spelling, and punctuation. If you see an underlined word or text passage, click on the highlighted area for correction options and apply them as needed. To make sure your sentences are clear and your word choice is perfect, double
【tool:pubmed_search】
{"ok": true, "query": "BOLERO-2 everolimus exemestane erratum abstract", "results": []}
【tool:web_search】
{"ok": true, "query": "BOLERO-2 abstract erratum investigator-assessed progression-free survival PMC", "results": [{"title": "Progression-free or overall survival…revisited in BOLERO-2 - PMC", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4080643/", "snippet": "Data presented by Dr. Piccart showed that after progression on study treatment, a somewhat higher fraction of subjects in the control arm received chemotherapy and a slightly higher fraction in the everolimus arm received further endocrine therapy. So how should we consider the results of BOLERO-2 trial?"}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal ..."}, {"title": "PDF Erratum to: Everolimus Plus Exemestane in Postmenopausal ... - Springer", "url": "https://link.springer.com/content/pdf/10.1007/s12325-014-0150-8.pdf", "snippet": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi Michael Gnant • Gabriel N. Hortobagyi Bohuslav Melichar • Katarina Petrakova Wentao Feng • Ayelet Cahana • Tetiana Taran"}, {"title": "Progression-free or overall survival…revisited in BOLERO-2", "url": "https://w
→ call web_fetch({"max_chars":5000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
→ call web_search({"limit":10,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract"})
→ call web_search({"limit":10,"query":"BOLERO-2 final progression-free survival analysis abstract prospectively defined subgroup"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" abstract", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "ABSTRACT Introduction: positive (HR?) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy . Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III tria [ abstract ]."}, {"title": "Everolimus plus exemestane in postmenopausal patients with HR ...", "url": "https://europepmc.org/article/MED/24158787", "snippet": "Characterization of the overall survival benefit in ENCORE 301, a randomized placebo-controlled phase II study of exemestane with and without entinostat in ER+ postmenopausal women with metastatic breast cancer [ abstract ]."}, {"title": "Everolimus Plus Exemestane in Postmenopausal ... - Semantic Scholar", "url": "https://www.semanticscholar.org/paper/Everolimus-Plus-Exemestane-in-Postmenopausal-with-Yardley-Noguchi/18628012e9bd5552cb865900148821bee522c82c", "snippet": "The addition of everolimus to exemestane markedly prolonged PFS in patients with HR+ advanced BC with disease recurrence/progression following prior NSAIs, and results further support the use ofEverolimus plus exemstane in this patient population. Intro
【tool:web_search】
{"ok": true, "query": "BOLERO-2 final progression-free survival analysis abstract prospectively defined subgroup", "results": [{"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Abstract . Introduction: Treatment options for postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC) who relapse or progress on a nonsteroidal aromatase inhibitor (NSAI) are limited. Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor ..."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://www.semanticscholar.org/paper/Abstract-P6-04-02:-Final-progression-free-survival-Piccart-Baselga/d02893186b0ec4a19beb20679761811e352cf45a", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}, {"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://www.researchgate.net/publication/2754282
→ call web_fetch({"max_chars":4500,"url":"https://link.springer.com/article/10.1007/s12325-013-0060-1"})
→ call web_fetch({"max_chars":4000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/"})
→ call web_fetch({"max_chars":3500,"url":"https://europepmc.org/article/MED/24158787"})
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | Advances in Therapy | Springer Nature Link Skip to main content Advertisement Log in Menu Find a journal Publish with us Track your research Search Saved research Cart Home Advances in Therapy Article Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Original Research Open access Published: 25 October 2013 Volume 30 , pages 870–884, ( 2013 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Advances in Therapy Aims and scope Submit manuscript Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Download PDF Denise A. Yardley 1 , Shinzaburo Noguchi 2 , Kathleen I. Pritchard 3 , Howard A. Burris III 1 , José Baselga 4 , Michael Gnant 5 , Gabriel N. Hortobagyi 6 , Mario Campone 7 , Barbara Pistilli 8 , Martine Piccart 9 , Bohuslav Melichar 10 , Katarina Petrakova 11 , Francis P. Arena 12 , Frans Erdkamp 13 , Wael A. Harb 14 , Wentao Feng 15 , Ayelet Cahana 15 , Tetiana Taran 15 , David Lebwohl 15 & … Hope S. Rugo 16 Show authors 24k Accesses 492 Citations 41 Altmetric 2 Mentions Explore al
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Adv Ther . 2014 Sep 11;31:1008–1009. doi: 10.1007/s12325-014-0150-8 Search in PMC Search in PubMed View in NLM Catalog Add to search Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A Yardley De
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/24158787", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
→ call run_python({"code":"import requests, bs4, re\nurl='https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/'\nhtml=requests.get(url,timeout=20).text\nprint('len',len(html))\nsoup=bs4.BeautifulSoup(html,'html.parser')\ntext=soup.get_text(' ',strip=True)\nfor pat in ['prospectively defined','recur','adjuvant therapy','Abstract']:\n idx=text.find(pat)\n print('\\nPAT',pat,'idx',idx)\n if idx!=-1:\n pri)
【tool:run_python】
{"ok": true, "stdout": "len 107141\n\nPAT prospectively defined idx 6476\norrects the article \" Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis \" in volume 30 on page 870. Erratum to: Adv Ther (2013) 30(10):870�884 DOI 10.1007/s12325-013-0060-1 The authors of the above-mentioned paper noticed an error subsequent to publication. In the Abstract, patients with disease recurrence during or within 12�months of completion of adjuvant therapy are grouped with other patient subgroups as being �prospectively defined�. This subgroup was not included within the prospectively defined patient subgroups for the BOLERO-2 trial. Of note, within the article (i.e., in the Results section and in Fig.�2), this subgroup is described using the correct terminology. All subgroups shown in Fig.�2 were prospectively defined with the exception of prior chemotherapy for metastatic disease (no/yes) and last therapy setting (adjuvant/metastatic). The incorrect sentence in the abstract is: Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2�months, respectively; hazard ratio�=�0.45 (95% confidence interval 0.38�0.54); log-rank P <�0.0001; central review: 11.0 versus 4.1�months, respectively; hazard ratio�=�0.38 (95% confidence interval 0.31�0.48); log-rank P <�0.0001] in the
→ call run_python({"code":"import requests, re, bs4\nhtml=requests.get('https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/',timeout=20).text\ntext=bs4.BeautifulSoup(html,'html.parser').get_text(' ',strip=True)\n# normalize unicode dashes and spaces\ntext=text.replace('\\u2013','-').replace('\\u2014','-').replace('\\u2018',\"'\").replace('\\u2019',\"'\").replace('\\u201c','\"').replace('\\u201d','\"').replace('\\xa0')
【tool:run_python】
{"ok": true, "stdout": "matched False\n.\n", "stderr": "", "returncode": 0}
→ call run_python({"code":"import requests, re, bs4\nhtml=requests.get('https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/',timeout=20).text\ntext=bs4.BeautifulSoup(html,'html.parser').get_text(' ',strip=True)\ntext=text.replace('\\u2013','-').replace('\\u2014','-').replace('\\u2018',\"'\").replace('\\u2019',\"'\").replace('\\u201c','\"').replace('\\u201d','\"').replace('\\xa0',' ')\nidx=text.find('The correct sente)
【tool:run_python】
{"ok": true, "stdout": "idx -1\n.\n", "stderr": "", "returncode": 0}
→ call run_python({"code":"import requests, bs4, re\nhtml=requests.get('https://pmc.ncbi.nlm.nih.gov/articles/PMC4713958/',timeout=20).text\ntext=bs4.BeautifulSoup(html,'html.parser').get_text(' ',strip=True)\n# show around 'incorrect sentence' and 'correct sentence'\nfor pat in ['incorrect sentence','correct sentence','prospectively defined','This subgroup was not included']:\n idx=text.lower().find(pat.lower())
【tool:run_python】
{"ok": true, "stdout": "ncluded within the prospectively defined patient subgroups for the BOLERO-2 trial. Of note, within the article (i.e., in the Results section and in Fig.�2), this subgroup is described using the correct terminology. All subgroups shown in Fig.�2 were prospectively defined with the exception of prior chemotherapy for metastatic disease (no/yes) and last therapy setting (adjuvant/metastatic). The incorrect sentence in the abstract is: Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2�months, respectively; hazard ratio�=�0.45 (95% confidence interval 0.38�0.54); log-rank P <�0.0001; central review: 11.0 versus 4.1�months, respectively; hazard ratio�=�0.38 (95% confidence interval 0.31�0.48); log-rank P <�0.0001] in the overall population and in all prospectively defined subgroups, including patients with visceral metastases, patients with recurrence during or within 12�months of completion of adjuvant therapy, and irrespective of age. The correct sentence should read: Final study results with median 18-month follow-up show that median PFS remained significantly longer with everolimus plus exemestane versus placebo plus exemestane [investigator review: 7.8 versus 3.2�months, respectively; hazard ratio�=�0.45 (95% confidence interval 0.38�0.54); log-rank P <�0.0001; central review: 11.0 versus 4.1�months, res
→ call write_note({"tags":["fact","4360dd15","clinical-trials","erratum","evidence-chain"],"text":"!! BOLERO-2 erratum 的最终可引用摘要句\n\n来源：[[PMC4713958]]（Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis）\n\n''被更正的唯一摘要句末尾''：\n原句写作 “... in the overall population and in all prospectively defined subgroups, including patients with vi)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_erratum_corrected_abstract_sentence.tid", "title": "BOLERO-2 erratum corrected abstract sentence"}
【assistant】
本轮已完成最小可验证任务：逐字比对 BOLERO-2 原摘要与 erratum，确认最终应引用的修订句。
结论：
- erratum 只删除了“patients with recurrence during or within 12 months of completion of adjuvant therapy”这段亚组表述；
- PFS 数值、HR、CI、P 值都未变；
- 可引用版本应使用 erratum 中的修订句，而不是原摘要句。
我已把可复现核查路径写入记忆：直接查 [[PMC4713958]] 并搜索 “The correct sentence should read”。
<NEXT_FOCUS>把这条修订句与原始摘要做逐词 diff，产出一个可直接贴入文稿的“原句→修订句”对照片段。</NEXT_FOCUS>